Abstract Number: 2384 • 2019 ACR/ARP Annual Meeting
Yoga Improves Fatigue and Mental Health in Rheumatoid Arthritis: Preliminary Results of a Randomized Controlled Trial
Background/Purpose: Rheumatoid arthritis (RA) patients perceive reduced health-related quality of life (HRQOL) through functional disability, pain, increased fatigue and impaired psychological functioning. Previous trials demonstrated…Abstract Number: 2385 • 2019 ACR/ARP Annual Meeting
Efficacy and Safety of Chinese Herbal Medicine Biqi Capsule Combined with Methotrexate in Patients with Rheumatoid Arthritis: A Pilot Study
Background/Purpose: In recent years, the combination therapies of conventional synthetic disease-modifying antirheumatic drugs (cDMARDs) with Chinses medicine has prevailed for the treatment of rheumatoid arthritis…Abstract Number: 2386 • 2019 ACR/ARP Annual Meeting
Consensus Statement and Recommendations on Methotrexate Use in Combined Therapy with Biological or Targeted Synthetic Disease Modifying Drugs in Patients with Rheumatoid Arthritis
Background/Purpose: Our aim was to develop recommendations for the management of methotrexate (MTX) when considering the combination with biological (b) or targeted synthetic (ts) disease…Abstract Number: 2387 • 2019 ACR/ARP Annual Meeting
Management of Patients with Incident Rheumatoid Arthritis in Rheumatology Clinical Practice
Background/Purpose: Treatment of Rheumatoid Arthritis (RA) has changed drastically in the last two decades in strategies and objectives, as well as in therapeutic options, especially…Abstract Number: 2388 • 2019 ACR/ARP Annual Meeting
Patient Characteristics Associated with Long Term Glucocorticoid Use in a Commercially Insured Incident RA Cohort
Background/Purpose: Prior descriptive work revealed high rates of long term (≥3 months) glucocorticoid (GC) utilization in a commercially insured incident RA cohort [1]. We aim…Abstract Number: 2389 • 2019 ACR/ARP Annual Meeting
Treat to Target by Specific Cytokine Interdiction: Multiple Biomarker Disease Activity Test Deconstructed
Background/Purpose: Rheumatologists have been encouraged to achieve low disease activity state when treating rheumatoid arthritis (RA). If it cannot be achieved with initial therapy, experts…Abstract Number: 2390 • 2019 ACR/ARP Annual Meeting
Prediction of Disease Relapses by Multi-biomarker Disease Activity Score and Autoantibody Status in RA Patients Tapering DMARD Treatment in Stable Remission
Background/Purpose: Achieving remission is the ultimate treatment goal in patients with rheumatoid arthritis (RA). With the development and wider use of highly effective disease modifying…Abstract Number: 2391 • 2019 ACR/ARP Annual Meeting
Effect of Biologics on the Hemoglobin A1c in a Population of Rheumatoid Arthritis Patients
Background/Purpose: Tumor necrosis factor (TNF), a pathogenic inflammatory mediator in Rheumatoid Arthritis (RA), has been shown to play an essential role in the pathophysiology of insulin resistance.…Abstract Number: 2392 • 2019 ACR/ARP Annual Meeting
The Effectiveness of anti-IL-6 Therapy to Elderly-onset Rheumatoid Arthritis
Background/Purpose: In daily practice, our rheumatologist has experienced different clinical feature of elderly-onset rheumatoid arthritis (EORA) compared with younger-onset RA (YORA). In EORA patients, serological…Abstract Number: 2393 • 2019 ACR/ARP Annual Meeting
Risk of Thromboembolism with Janus Kinase Inhibitors: A Systematic Review and Meta-Analysis of Randomized Placebo Controlled Trials
Background/Purpose: Importance The efficacy of Janus kinase (JAK) inhibitors is well established across a range of diseases. However, there is a major concern regarding the potential risk of an increased…Abstract Number: 2394 • 2019 ACR/ARP Annual Meeting
Use and Influence of Biologic/Janus Kinase Monotherapy Among Recently Switched Rheumatoid Arthritis Patients: Results from an Annual National Patient Chart Audit
Background/Purpose: US rheumatologists have long agreed that methotrexate (MTX) is the backbone of rheumatoid arthritis (RA) treatment, and while comfort with biologic/JAK monotherapy is growing,…Abstract Number: 2395 • 2019 ACR/ARP Annual Meeting
DMARD-naïve Rheumatoid Arthritis (RA) Patients Have Greater RAPID3 Improvement over 6 Months After 1st Visit Than Patients Who Were Treated Previously Treated with DMARDs, Although Baseline RAPID3 Was Similar: The Importance of Early Treatment
Background/Purpose: A study of patients with RA at their first visit to an academic rheumatology site indicated an unexpected observation that 75% of patients had…Abstract Number: 2396 • 2019 ACR/ARP Annual Meeting
DNA Methylation of the Dual Specificity Phosphatase 22 (DUSP22) Gene Promoter in Plasma and Medication Use in Rheumatoid Arthritis (RA)
Background/Purpose: The Dual Specificity Phosphatase 22 (DUSP22) gene expression has been shown to be regulated via DNA methylation of its promoter. In addition, aberrant DNA…Abstract Number: 2397 • 2019 ACR/ARP Annual Meeting
Skin Lesions as a Side Effect of anti-IL6 Therapy: Transcriptome Analysis of Peripheral Blood Shows a Risk of Paradoxical Neutrophil Activation and Exacerbation of Skin Ulcer
Background/Purpose: Skin lesion as a side effect of Tocilizumab (TCZ) has not been paid much attention. In the drug information sheets, incidence of dermatological adverse…Abstract Number: 2398 • 2019 ACR/ARP Annual Meeting
Prevalence of Anxiety and Depression in a Cohort of Patients with Rheumatic Diseases on Biological Infusions
Background/Purpose: Studies have shown an increased prevalence of psychologic disorders in rheumatic diseases, such as rheumatoid arthritis, systemic lupus erythematosus, and psoriatic arthritis, compared to…
ACR Meeting Abstracts